Compare the CTC clearance rate of HER2‐negative metastatic BC patients with ≥ 1/7.5mL HER2‐positive CTC (using the CellSearch® system coupled with the evaluation of the HER2 status by IHC or FISH) randomized to standard treatment with or without lapatinib. Here, ERBB2 is linked to breast cancer.